Wall Street analysts forecast that Achillion Pharmaceuticals (NASDAQ:ACHN) will post earnings per share (EPS) of ($0.14) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Achillion Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.14). Achillion Pharmaceuticals posted earnings of ($0.15) per share during the same quarter last year, which would indicate a positive year over year growth rate of 6.7%. The business is scheduled to issue its next quarterly earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that Achillion Pharmaceuticals will report full-year earnings of ($0.55) per share for the current fiscal year, with EPS estimates ranging from ($0.56) to ($0.55). For the next year, analysts expect that the business will post earnings of ($0.59) per share, with EPS estimates ranging from ($0.62) to ($0.51). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Achillion Pharmaceuticals.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.01). During the same period in the previous year, the company earned ($0.03) earnings per share.
Several research firms have recently commented on ACHN. BidaskClub lowered Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 13th. B. Riley began coverage on Achillion Pharmaceuticals in a research report on Thursday, February 8th. They issued a “neutral” rating and a $3.50 price target for the company. Zacks Investment Research lowered Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, Leerink Swann reissued a “buy” rating and issued a $5.00 price target on shares of Achillion Pharmaceuticals in a research report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $4.89.
Large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP increased its position in Achillion Pharmaceuticals by 75.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,276,076 shares of the biopharmaceutical company’s stock valued at $14,710,000 after buying an additional 1,407,108 shares in the last quarter. Matisse Capital increased its position in Achillion Pharmaceuticals by 15.8% during the 4th quarter. Matisse Capital now owns 135,445 shares of the biopharmaceutical company’s stock valued at $390,000 after buying an additional 18,500 shares in the last quarter. BVF Inc. IL acquired a new position in Achillion Pharmaceuticals during the 4th quarter valued at about $4,632,000. Sarissa Capital Management LP acquired a new position in Achillion Pharmaceuticals during the 3rd quarter valued at about $9,594,000. Finally, RTW Investments LP increased its position in Achillion Pharmaceuticals by 72.8% during the 4th quarter. RTW Investments LP now owns 13,546,902 shares of the biopharmaceutical company’s stock valued at $39,015,000 after buying an additional 5,707,136 shares in the last quarter. 82.04% of the stock is currently owned by institutional investors.
ACHN opened at $3.38 on Friday. The firm has a market capitalization of $489.52, a PE ratio of -5.63 and a beta of 0.89. Achillion Pharmaceuticals has a 12 month low of $2.58 and a 12 month high of $5.66.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.